By a News Reporter-Staff News Editor at Insurance Daily News-- Current study results on Oncology- Liver Cancer have been published. According to news originating from Busan, South Korea, by NewsRx ...
Liver cancer continues to be one of the deadliest and increasingly common cancers worldwide. Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality worldwide. Despite ...
Glypican-3 (GPC3) has emerged as a promising immunotherapeutic target for hepatocellular carcinoma (HCC). However, its ...
Preserved liver function and absence of metabolic dysfunction-associated steatotic liver disease or varices were associated with longer survival.
What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and ...
A Memphis teen who has already endured unimaginable health challenges got to celebrate her quinceañera as planned this summer ...
Immunotherapy-based combinations appear to provide greater benefit than multi-kinase inhibitors for these patients.
One patient has glioblastoma multiforme (GBM), and the other patient has advanced hepatocellular carcinoma (HCC) treated in the second line. Neither patient has experienced PIC-related adverse events ...
Discover a study showing how HCV eradication with antivirals during immunotherapy improves survival, liver function, and ...
MASLD and Liver Cancer: What’s the Link? Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition where too much fat builds up in your liver. Unlike fatty liver caused by heavy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback